Articles by Tom von Gunden
-
Long-Acting Injectable Formulations Targeting Opioid Overdose With Elysium's Tom Jenkins
9/17/2025
Not only do opioid overdose sufferers need urgent, rescue treatments but they often remain vulnerable to symptom rebound and continued opioid use disorder (OUD). In this episode of Sit and Deliver, Tom Jenkins, Chief Scientific Officer of biopharmaceutical company Elysium Therapeutics, talks with videocast host Tom von Gunden about mitigating recurrence by using long-acting, intramuscular injectables (LAIs) to deliver the rescue drug naloxone in a rapid onset, slow-off formulation.
-
Expanding Therapeutic Targets For Injection And Inhalation With Phillips Medisize's Geraldine Venthoye
8/28/2025
Chief Scientific Officer Geraldine Venthoye from Phillips Medisize joins Supplier Horizons host Tom von Gunden in a conversation about advancements in inhalation and injection for targeting a broader range of patient needs. The two discuss formulation and delivery system challenges for complex, large molecule biologics, including vaccines, immunotherapies, and cell and gene therapies. Venthoye comments on patient access and affordability, digital health and connected devices, chronic disease management, and social and environmental stewardship.
-
DARPin-Delivered Radiotherapy With Molecular Partners And Orano Med
8/20/2025
In this episode of In Combination, CEO Patrick Amstutz of Molecular Partners and CEO Arnaud Lesegretain of Orano Med join host Tom von Gunden in a discussion of using DARPins (Designed Ankyrin Repeat Proteins) as vector delivery platforms for high-affinity binding of radioisotopes to treat cancer. Using the example of small cell lung cancer. Patrick and Arnaud describe how DARPin-delivered radiotherapy can attack metastatic cancers while overcoming the targeting limitations of external beam radiation and of antibodies.
-
Understanding The Global Regulatory Landscape For Combination Products
8/14/2025
In this videocast episode, host Tom von Gunden discusses Chapter 14 of The Combination Products Handbook (CRC Press) with the book’s editor Susan Neadle, along with chapter coauthors Stephanie Goebel, Cherry Malonzo Marty, and Viky Verna. The group provides overviews of the commonalities and variances in regulatory definitions and guidances for combination products across global jurisdictions and agencies.
-
Crossing The Blood-Brain Barrier To Target Tumors With CNS Pharmaceuticals
7/31/2025
Targeting glioblastoma (GBM) and other malignant brain tumors brings with it the long-standing challenge of crossing the blood-brain barrier, or BBB. In this episode of Sit and Deliver, host Tom von Gunden talks with CEO John Climaco and Chief Medical Officer Dr. Sandra Silberman from CNS Pharmaceuticals about intravenously crossing the BBB to deliver classes of drugs, such as taxanes, proven in treating solid tumors in other locations.
-
Leveraging Nanoparticles For High Drug Load Delivery With Nanoform's Christian Jones
7/28/2025
In this episode of Supplier Horizons, host Tom von Gunden talks with Chief Commercial Officer Christian Jones of nanoparticle technology developer Nanoform about innovation in drug and biologics delivery. The discussion covers aspects of patient centricity such as aging populations, in-home self-administration, and personalized medicine. It also focuses on the use of nanotechnology in the delivery of high concentration formulations via oral and subcutaneous routes of administration.
-
Leveraging Combination Products For Biologics Delivery
7/22/2025
In this episode of The Combination Products Handbook: The Series, host Tom von Gunden discusses Chapter 12 on biologics delivery with chapter author Manfred Maeder and the book’s editor, Susan Neadle. Manfred and Susan comment on the challenges of moving large molecule formulations into combination products while considering product stability, usability, and supply chain.
-
Charting The Waters Of Drug Delivery Innovation With Suttons Creek
7/11/2025
In this episode of In Combination, the technical leadership team from device consultancy Suttons Creek joins host Tom von Gunden to discuss trends in the patient landscape driving innovation in drug delivery, including combination products and therapies. The conversation covers patient self-administration, emerging modalities, and key considerations in product development, regulatory pathways, and the supply chain.
-
Drug Delivery For Various Molecules And Modalities
6/24/2025
In this episode of Sit and Deliver, host Tom von Gunden talks with Merck VP of Pharmaceutical Sciences and Clinical Supply Allen Templeton about formulation and device considerations for combination products and other delivery systems deployed across a range of molecule types and sizes. The conversation takes them from small molecules, through peptides and mAbs, to large molecule biologics, across various routes of administration including oral, injectable, and inhalation.
-
Trends And Advances In Inhalation Delivery With Kindeva's Stephen Stein
6/16/2025
Stephen Stein, scientific director of inhalation products at Kindeva, joins Supplier Horizons host Tom von Gunden in a discussion of opportunities and challenges for inhalation product development. The topics discussed include ensuring bioequivalence in generics, reducing environmental impact from propellants, and advancing inhalation-based delivery of vaccines and combination therapies.